IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.9 Million USD | -21.24% |
| 2022 | 2.41 Million USD | -35.6% |
| 2021 | 3.74 Million USD | -2.65% |
| 2020 | 3.84 Million USD | 12.26% |
| 2019 | 3.42 Million USD | -12.75% |
| 2018 | 3.92 Million GBP | 60.91% |
| 2017 | 2.44 Million GBP | 17.71% |
| 2016 | 2.07 Million GBP | 35.59% |
| 2015 | 1.53 Million GBP | -4.43% |
| 2014 | 1.6 Million GBP | 2.5% |
| 2013 | 1.56 Million GBP | -29.48% |
| 2012 | 2.21 Million GBP | -15.89% |
| 2011 | 2.63 Million GBP | 132.01% |
| 2010 | 1.13 Million GBP | -35.03% |
| 2009 | 1.74 Million GBP | 30.96% |
| 2008 | 1.33 Million GBP | -1.4% |
| 2007 | 1.35 Million GBP | -22.15% |
| 2006 | 1.73 Million GBP | -23.06% |
| 2005 | 2.25 Million GBP | 0.0% |
| 2004 | 2.25 Million GBP | 24.39% |
| 2003 | 1.81 Million GBP | -7.01% |
| 2002 | 1.95 Million GBP | 81.67% |
| 2001 | 1.07 Million GBP | 13.28% |
| 2000 | 949 Thousand GBP | -16.68% |
| 1999 | 1.13 Million GBP | 47.73% |
| 1998 | 771 Thousand GBP | 1.45% |
| 1997 | 760 Thousand GBP | 93.88% |
| 1996 | 392 Thousand GBP | -86.29% |
| 1995 | 2.85 Million GBP | -1.31% |
| 1994 | 2.89 Million GBP | 200.21% |
| 1993 | 965 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.95 Million GBP | 2.77% |
| 2024 Q2 | 1.93 Million USD | 0.0% |
| 2023 Q4 | 1.9 Million USD | -3.96% |
| 2023 Q1 | 2.29 Million GBP | -4.96% |
| 2023 Q3 | 1.97 Million GBP | -15.43% |
| 2023 Q2 | 2.33 Million USD | 2.02% |
| 2023 FY | 1.9 Million USD | -21.24% |
| 2022 Q1 | 2.75 Million GBP | -30.17% |
| 2022 Q2 | 2.67 Million GBP | -2.89% |
| 2022 Q3 | 2.63 Million GBP | -1.62% |
| 2022 FY | 2.41 Million USD | -35.6% |
| 2022 Q4 | 2.41 Million USD | -8.32% |
| 2021 Q3 | 3.84 Million GBP | -5.84% |
| 2021 Q1 | 4.04 Million GBP | 5.21% |
| 2021 FY | 3.74 Million USD | -2.65% |
| 2021 Q4 | 3.94 Million GBP | 2.54% |
| 2021 Q2 | 4.08 Million GBP | 0.89% |
| 2020 Q4 | 3.84 Million GBP | 4.34% |
| 2020 Q1 | 2.52 Million GBP | -26.39% |
| 2020 Q2 | 2.52 Million GBP | -0.01% |
| 2020 FY | 3.84 Million USD | 12.26% |
| 2020 Q3 | 3.68 Million GBP | 46.19% |
| 2019 Q2 | 2.55 Million GBP | -21.56% |
| 2019 FY | 3.42 Million USD | -12.75% |
| 2019 Q3 | 3.53 Million GBP | 38.55% |
| 2019 Q1 | 3.25 Million GBP | 7.89% |
| 2019 Q4 | 3.42 Million GBP | -2.96% |
| 2018 Q2 | 2.21 Million GBP | -25.59% |
| 2018 FY | 3.92 Million GBP | 60.91% |
| 2018 Q4 | 3.01 Million GBP | -24.23% |
| 2018 Q3 | 3.97 Million GBP | 79.29% |
| 2018 Q1 | 2.98 Million GBP | 63.79% |
| 2017 FY | 2.44 Million GBP | 17.71% |
| 2017 Q4 | 1.82 Million GBP | -22.42% |
| 2017 Q3 | 2.34 Million GBP | 42.7% |
| 2017 Q2 | 1.64 Million GBP | -17.39% |
| 2017 Q1 | 1.99 Million GBP | 9.77% |
| 2016 Q3 | 1.97 Million GBP | 14.25% |
| 2016 FY | 2.07 Million GBP | 35.59% |
| 2016 Q2 | 1.72 Million GBP | -19.69% |
| 2016 Q1 | 2.15 Million GBP | 40.63% |
| 2016 Q4 | 1.81 Million GBP | -8.17% |
| 2015 Q2 | 1.37 Million GBP | -31.28% |
| 2015 FY | 1.53 Million GBP | -4.43% |
| 2015 Q3 | 2.31 Million GBP | 68.37% |
| 2015 Q1 | 1.99 Million GBP | 24.8% |
| 2015 Q4 | 1.53 Million GBP | -33.81% |
| 2014 FY | 1.6 Million GBP | 2.5% |
| 2014 Q1 | 2.18 Million GBP | 39.57% |
| 2014 Q4 | 1.6 Million GBP | 0.0% |
| 2014 Q2 | 1.43 Million GBP | -34.27% |
| 2013 FY | 1.56 Million GBP | -29.48% |
| 2013 Q2 | 1.28 Million GBP | 0.0% |
| 2013 Q4 | 1.56 Million GBP | 0.0% |
| 2012 Q4 | 2.21 Million GBP | 0.0% |
| 2012 FY | 2.21 Million GBP | -15.89% |
| 2012 Q2 | 3.02 Million GBP | 0.0% |
| 2011 FY | 2.63 Million GBP | 132.01% |
| 2011 Q2 | 1.25 Million GBP | 0.0% |
| 2011 Q4 | 2.63 Million GBP | 0.0% |
| 2010 Q2 | 1.68 Million GBP | 0.0% |
| 2010 FY | 1.13 Million GBP | -35.03% |
| 2010 Q4 | 1.13 Million GBP | 0.0% |
| 2009 Q4 | 1.74 Million GBP | 0.0% |
| 2009 Q2 | 1.94 Million GBP | 0.0% |
| 2009 FY | 1.74 Million GBP | 30.96% |
| 2008 Q4 | 1.33 Million GBP | 0.0% |
| 2008 FY | 1.33 Million GBP | -1.4% |
| 2008 Q2 | 1.94 Million GBP | 0.0% |
| 2007 FY | 1.35 Million GBP | -22.15% |
| 2007 Q2 | 1.73 Million GBP | 0.0% |
| 2006 Q4 | 1.73 Million GBP | 0.0% |
| 2006 Q2 | 2.16 Million GBP | 0.0% |
| 2006 FY | 1.73 Million GBP | -23.06% |
| 2005 Q4 | 2.25 Million GBP | 0.0% |
| 2005 FY | 2.25 Million GBP | 0.0% |
| 2005 Q2 | 4.28 Million GBP | 0.0% |
| 2004 Q2 | 938.02 Thousand GBP | 0.0% |
| 2004 Q4 | 2.25 Million GBP | 0.0% |
| 2004 FY | 2.25 Million GBP | 24.39% |
| 2003 Q4 | 1.81 Million GBP | 0.0% |
| 2003 FY | 1.81 Million GBP | -7.01% |
| 2003 Q2 | 1.14 Million GBP | 0.0% |
| 2002 Q2 | 1.45 Million GBP | 0.0% |
| 2002 FY | 1.95 Million GBP | 81.67% |
| 2002 Q4 | 1.95 Million GBP | 0.0% |
| 2001 FY | 1.07 Million GBP | 13.28% |
| 2000 FY | 949 Thousand GBP | -16.68% |
| 1999 FY | 1.13 Million GBP | 47.73% |
| 1998 FY | 771 Thousand GBP | 1.45% |
| 1997 FY | 760 Thousand GBP | 93.88% |
| 1996 FY | 392 Thousand GBP | -86.29% |
| 1995 FY | 2.85 Million GBP | -1.31% |
| 1994 FY | 2.89 Million GBP | 200.21% |
| 1993 FY | 965 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -6827.029% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 79.925% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.378% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -134.954% |
| Rebus Holdings, Inc. | 5.24 Million USD | 63.749% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.78% |
| Qrons Inc. | 1.48 Million USD | -27.647% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -54.972% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.464% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4151.593% |
| Skye Bioscience, Inc. | 14.07 Million USD | 86.496% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.435% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 80.168% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -350.768% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.202% |
| Intellipharmaceutics International Inc. | 12 Million USD | 84.176% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 50.66% |
| Mesoblast Limited | 188.44 Million USD | 98.992% |
| Marizyme, Inc. | 26.67 Million USD | 92.876% |
| Genus plc | 485 Million USD | 99.608% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 67.475% |
| Pharming Group N.V. | 244.07 Million USD | 99.221% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 5.464% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 24.482% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 49.992% |
| ContraFect Corporation | 32.53 Million USD | 94.159% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 4.089% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 50.354% |
| IMV Inc. | 37.93 Million USD | 94.99% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 83.866% |
| MultiCell Technologies, Inc. | 1617.67 USD | -117370.93% |
| ONE Bio Corp. | 27.49 Million USD | 93.089% |
| Accustem Sciences Inc. | 1.07 Million USD | -76.077% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.545% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 10.155% |
| Q BioMed Inc. | 8.13 Million USD | 76.635% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.709% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 63.073% |
| Biomind Labs Inc. | 1.49 Million USD | -26.803% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.399% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 78.984% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 89.674% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -32.53% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1237.339% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -844.874% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 66.927% |
| GB Sciences, Inc. | 5.41 Million USD | 64.923% |
| Alpha Cognition Inc. | 7.16 Million USD | 73.477% |
| HST Global, Inc. | 593.59 Thousand USD | -220.134% |
| CSL Limited | 18.62 Billion USD | 99.99% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -50.913% |
| Halberd Corporation | 728.71 Thousand USD | -160.772% |
| Enzolytics Inc. | 365.26 Million USD | 99.48% |
| Agentix Corp. | 2.51 Million USD | 24.308% |
| Resverlogix Corp. | 67.39 Million USD | 97.18% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -126.567% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.573% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -10.869% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 92.321% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 84.035% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 48.153% |
| AVAX Technologies, Inc. | 3.99 Million USD | 52.418% |
| Zenith Capital Corp. | 27.56 Thousand USD | -6792.858% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.857% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -696.254% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 49.113% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -179.112% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 29.921% |
| Kadimastem Ltd | 3.5 Million USD | 45.781% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2739.265% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.219% |
| BioStem Technologies, Inc. | 15.9 Million USD | 88.052% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -308.93% |
| LadRx Corporation | 2.2 Million USD | 13.644% |
| Cell Source, Inc. | 15.8 Million USD | 87.978% |
| Regen BioPharma, Inc. | 5.45 Million USD | 65.181% |
| Regen BioPharma, Inc. | 5.45 Million USD | 65.181% |
| NovAccess Global Inc. | 7.86 Million USD | 75.826% |
| Affymax, Inc. | 8.87 Million USD | 78.579% |
| Itoco Inc. | 1.65 Million USD | -14.95% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 7.374% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 68.585% |
| Mobile Lads Corp. | 1.31 Million USD | -44.674% |
| CytoDyn Inc. | 127.89 Million USD | 98.514% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4446.262% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -21.318% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 82.795% |
| SYBLEU INC | 681.41 Thousand USD | -178.875% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 68.857% |
| International Stem Cell Corporation | 5.27 Million USD | 63.989% |
| Bioxytran, Inc. | 3.24 Million USD | 41.52% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -203.654% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 58.843% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.365% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 91.465% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 6.176% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 65.31% |
| Neutra Corp. | 973.52 Thousand USD | -95.196% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 93.451% |
| PureTech Health plc | 125.58 Million USD | 98.487% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 49.422% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.743% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.161% |
| CSL Limited | 18.62 Billion USD | 99.99% |
| Cellectis S.A. | 249.36 Million USD | 99.238% |